Terms: = Pancreatic cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Prognosis
476 results:
1. Drugging the undruggable: Advances in targeting kras signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract] [Full Text] [Related]
2. Targeting kras in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract] [Full Text] [Related]
3. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
4. [The use of targeted therapies in gastrointestinal oncology].
Lange S
Dtsch Med Wochenschr; 2024 Apr; 149(8):440-446. PubMed ID: 38565117
[TBL] [Abstract] [Full Text] [Related]
5. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract] [Full Text] [Related]
6. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
7. Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human pancreatic Ductal Adenocarcinoma Cell Lines.
Zeppa L; Aguzzi C; Morelli MB; Marinelli O; Giangrossi M; Luongo M; Amantini C; Santoni G; Nabissi M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396679
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of the RAF/MEK/ERK Signaling Cascade in pancreatic cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract] [Full Text] [Related]
9. Exploring kras-mutant pancreatic ductal adenocarcinoma: a model validation study.
Yang F; He Y; Ge N; Guo J; Yang F; Sun S
Front Immunol; 2023; 14():1203459. PubMed ID: 38268915
[TBL] [Abstract] [Full Text] [Related]
10. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma.
Abe S; Masuda A; Matsumoto T; Inoue J; Toyama H; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Yamakawa K; Gonda M; Masuda S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Ko T; Yokotani Y; Oka Y; Ota S; Kanzawa M; Itoh T; Imai T; Fukumoto T; Hara E; Kodama Y
J Gastroenterol; 2024 Mar; 59(3):250-262. PubMed ID: 38242997
[TBL] [Abstract] [Full Text] [Related]
11. A novel method for detection of pancreatic Ductal Adenocarcinoma using explainable machine learning.
Aslam M; Rajbdad F; Azmat S; Li Z; Boudreaux JP; Thiagarajan R; Yao S; Xu J
Comput Methods Programs Biomed; 2024 Mar; 245():108019. PubMed ID: 38237450
[TBL] [Abstract] [Full Text] [Related]
12. Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways.
Juin A; Spence HJ; Machesky LM
J Pathol; 2024 Apr; 262(4):454-466. PubMed ID: 38229581
[TBL] [Abstract] [Full Text] [Related]
13. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
[TBL] [Abstract] [Full Text] [Related]
15. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
16. Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of cancer Cells Treated with the kras
Orsburn BC
J Proteome Res; 2023 Dec; 22(12):3703-3713. PubMed ID: 37983312
[TBL] [Abstract] [Full Text] [Related]
17. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma.
Detlefsen S; Boldt HB; Burton M; Thomsen MM; Rasmussen LG; Ørbeck SV; Pfeiffer P; Mortensen MB; de Stricker K
Hum Pathol; 2023 Dec; 142():68-80. PubMed ID: 37977512
[TBL] [Abstract] [Full Text] [Related]
18. The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas.
Sánchez-Tilló E; Pedrosa L; Vila I; Chen Y; Győrffy B; Sánchez-Moral L; Siles L; Lozano JJ; Esteve-Codina A; Darling DS; Cuatrecasas M; Castells A; Maurel J; Postigo A
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37870961
[TBL] [Abstract] [Full Text] [Related]
19. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma.
Koh Y; Kim H; Joo SY; Song S; Choi YH; Kim HR; Moon B; Byun J; Hong J; Shin DY; Park S; Lee KH; Lee KT; Lee JK; Park D; Lee SH; Jang JY; Lee H; Kim JA; Yoon SS; Park JK
J Transl Med; 2023 Oct; 21(1):730. PubMed ID: 37848935
[TBL] [Abstract] [Full Text] [Related]
20. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy.
Geerinckx B; Teuwen LA; Foo T; Vandamme T; Smith A; Peeters M; Price T
Expert Rev Anticancer Ther; 2023; 23(12):1237-1249. PubMed ID: 37842857
[TBL] [Abstract] [Full Text] [Related]
[Next]
